Pulmonary endpoints in clinical trials for children with cystic fibrosis under two years of age

Cystic fibrosis is a lifelong progressive disease in which lung disease is the main prognostic factor, where starting early treatment is crucial for improving long-term outcomes. Therefore, new treatment should be available as early as possible. However, choosing appropriate and feasible clinical trial endpoints in children under 2 years of age presents significant challenges. Most studies in this age group have extrapolated pulmonary efficacy from older age groups, focusing on safety, pharmacokinetics, and biomarker response. As lung health is near normal in infants, demonstrating absence of pulmonary decline requires large sample sizes and extended study duration, which may not be feasible for standard regulatory trials. To address this gap, the European Cystic Fibrosis Society Clinical Trials Network developed a consensus document evaluating direct pulmonary endpoints for therapeutic pulmonary studies in this young age group. The pulmonary endpoints evaluated include multiple-breath washout (MBW); chest computed tomography (CT); chest magnetic resonance imaging (MRI); airway infection and inflammation. Relevant literature, pitfalls, practice guidelines, and recommendations are presented. None of the pulmonary endpoints evaluated are currently suitable to serve as a primary efficacy endpoint in children below 2 years of age, as this will require large numbers and long follow-up. For clinical trials in infants with CF, pharmacokinetics, pharmacodynamics, safety and tolerability should remain the primary endpoints, with pulmonary endpoints as secondary or exploratory outcomes. Post authorization studies are essential to evaluate long-term pulmonary benefits, including MBW, structural lung assessment (e.g. CT and MRI), and markers of pulmonary inflammation to fully understand the impact of early therapy initiation in this young population.

Authors

Institutions

Publication Details

Journal
Journal of Cystic Fibrosis
Published
2025-07-01
DOI
https://doi.org/10.1016/j.jcf.2025.06.003
Citations
2
Primary Topic
Cystic Fibrosis Research Advances
Type
article
Field-Weighted Citation Impact
3.04

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pulmonary endpoints in clinical trials for children with cystic fibrosis under two years of age

Tim Lee, Anders Lindblad, Isabelle Sermet‐Gaudelus, Philippe Reix et al.
2 citations
Journal of Cystic Fibrosis
Cystic Fibrosis Research Advances
3.04
article

Pulmonary endpoints in clinical trials for children with cystic fibrosis under two years of age

Tim Lee, Anders Lindblad, Isabelle Sermet‐Gaudelus, Philippe Reix, Paul McNally, Hettie M. Janssens, Pierluigi Ciet, Gwyneth Davies, Anna‐Maria Dittrich, Jane C. Davies, Mirjam Stahl, Clare Saunders, Harm A.W.M. Tiddens, Daan Caudri, K. Hill
article en
2 citations

Abstract

Cystic fibrosis is a lifelong progressive disease in which lung disease is the main prognostic factor, where starting early treatment is crucial for improving long-term outcomes. Therefore, new treatment should be available as early as possible. However, choosing appropriate and feasible clinical trial endpoints in children under 2 years of age presents significant challenges. Most studies in this age group have extrapolated pulmonary efficacy from older age groups, focusing on safety, pharmacokinetics, and biomarker response. As lung health is near normal in infants, demonstrating absence of pulmonary decline requires large sample sizes and extended study duration, which may not be feasible for standard regulatory trials. To address this gap, the European Cystic Fibrosis Society Clinical Trials Network developed a consensus document evaluating direct pulmonary endpoints for therapeutic pulmonary studies in this young age group. The pulmonary endpoints evaluated include multiple-breath washout (MBW); chest computed tomography (CT); chest magnetic resonance imaging (MRI); airway infection and inflammation. Relevant literature, pitfalls, practice guidelines, and recommendations are presented. None of the pulmonary endpoints evaluated are currently suitable to serve as a primary efficacy endpoint in children below 2 years of age, as this will require large numbers and long follow-up. For clinical trials in infants with CF, pharmacokinetics, pharmacodynamics, safety and tolerability should remain the primary endpoints, with pulmonary endpoints as secondary or exploratory outcomes. Post authorization studies are essential to evaluate long-term pulmonary benefits, including MBW, structural lung assessment (e.g. CT and MRI), and markers of pulmonary inflammation to fully understand the impact of early therapy initiation in this young population.

Journal of Cystic FibrosisVol. 24(4)
Université Claude Bernard Lyon 1 (FR), Queen's University Belfast (GB), Hôpital Necker-Enfants Malades (FR), Centre National de la Recherche Scientifique (FR), Radboud University Nijmegen (NL), Inserm (FR), Université Paris Cité (FR), Cystic Fibrosis Trust (GB), Great Ormond Street Hospital for Children NHS Foundation Trust (GB), Erasmus MC (NL), Harefield Hospital (GB), Radboud University Medical Center (NL), Children's Health Ireland at Crumlin (IE), Medizinische Hochschule Hannover (DE), Humboldt-Universität zu Berlin (DE), Assistance Publique – Hôpitaux de Paris (FR), Drottning Silvias barn- och ungdomssjukhus (SE), Hospices Civils de Lyon (FR), Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE), Erasmus MC - Sophia Children’s Hospital (NL), University College London (GB)
UK Research and Innovation, National Institute for Health and Care Research, NIHR Imperial Biomedical Research Centre
Good health and well-being
Openalex Percentile: Top 9%
Cystic Fibrosis Research Advances
3.04
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.